🇺🇸 FDA
Patent

US 12215169

Anti-complement C1s antibodies and uses thereof

granted A61KA61K2039/54A61K2039/545

Quick answer

US patent 12215169 (Anti-complement C1s antibodies and uses thereof) held by Bioverativ USA Inc. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/54, A61K2039/545, A61P, A61P13/12